Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference

KANSAS CITY, Kan., Nov. 28, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will present at the 26th Annual Piper Jaffray Healthcare Conference, to be held December 2-3, 2014, at the New York Palace Hotel in New York.

Steven St. Peter, M.D., President and Chief Executive Officer, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

Event:


26th Annual Piper Jaffray Healthcare Conference

Date: 


Wednesday, December 3, 2014 

Time: 


9:30 am (Eastern Time) 

Location:


Rutherford, Track 5, The New York Palace Hotel

The presentations will be webcast live and remain available for 30 days following the presentation.  To access the webcasts, please visit the investor relations section of the Aratana website at aratana.investorroom.com.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.  

Contacts:
For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman
ctooman@aratana.com; (913) 353-1023

For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics

print email rss